Walmsley Under Pressure Over GSK’s Strategy
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.
You may also be interested in...
Sanofi and GSK are way behind in the COVID-19 vaccine race and the start of a rolling review of Vizprevtyn at the European Medicines Agency is an important step.
Activist investor Elliot Management – which has built up a sizeable stake in GSK – is urging the UK-based pharma giant to remain open to offers for its Consumer Healthcare business and to consider both internal and external candidates for the leadership of the standalone unit.
GSK will demerge its Consumer Healthcare business in mid-2022 and list the new company on the London Stock Exchange. The move will “create new world leader in consumer healthcare,” according to GSK, with annual sales in excess of £10bn.